Technologies Fueling Biopharma and Life Sciences Research

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology TOE depicts life sciences trends across the biopharmaceutical industry. Different genetic technologies, antibody drug conjugates, mitochondrial based therapies are illustrated. The corresponding clinical trials scenario is depicted, along with the industry interactions.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alte

Table of Contents

Technologies Fueling Biopharma and Life Sciences ResearchRecent Advances in Biopharma and Life Sciences Technologies Gene Therapy Advancement for High-Grade Glioma (HGG)Positive Phase-3 Results for RisankizumabDaiichi Sankyo and Glycotope Collaborate for Antibody Drug Conjugate (ADC) DevelopmentRole of Mitochondrial Networks in Healthy AgingClinical Trial Analysis and Industry InteractionsKey Clinical Studies Conducted by Tocagen Inc.Key Clinical Studies Conducted by Tocagen Inc.Summary of Key Contacts

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.